NCT06714630Recruiting
The PROSECCA Study, Answering New Questions in Prostate Cancer
Improving Radiotherapy in PROState Cancer Using EleCtronic Population-based healthCAre Data: The PROSECCA Study, Answering New Questions in Prostate Cancer
Source: ClinicalTrials.gov · Last updated 26 Aug 2026
Brief summary (registry, in English)
Nearly half of all cancer patients receive radiotherapy as part of their treatment and although it is effective at destroying cancerous lesions deep within the body, this comes at the cost of damaging healthy, or normal, tissues. With 50% of cancer patients surviving for 10 years or more, these patients can be left with life-changing side effects from their radiotherapy. It is clear that more must be done to limit damage to normal healthy tissue without compromising annihilation of the tumour and curing patients. The key to this is personalising an individual's radiotherapy treatment, in other words rather than assuming that all tumours respond similarly to radiotherapy, the treatment is optimised for an individual. To date, approaches to do this have been restricted to small numbers of carefully selected patients, are inordinately expensive, and not suitable for rolling out into everyday practice across the NHS. There is however another way, namely using Artificial Intelligence (AI) combined with an individual's healthcare record. By linking together large numbers of healthcare records at a national level, combined with the power of AI, the PROSECCA project will transform radiotherapy and cancer care.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 15000 (estimated)
- First submitted
- 13 Aug 2024
- Start date
- 1 Jul 2024
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- University of Edinburgh
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT06714630
What you commit to
- Study type: Observational
- Planned participants: 15000
- From 1 Jul 2024 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Incomplete course of radiotherapy
Other
- No PSA data
- No follow-up corresponding healthcare data available
- No imaging data available
Who the study is looking for
- External beam radiotherapy delivered by a linear accelerator
- Prostate Specific Antigen (PSA) recorded at regular intervals after radiotherapy
- Minimum of 10 year survival post-radiotherapy
- Diagnostic Computerised Tomography (CT) acquired
- Radiotherapy planning CT acquired
- Radiotherapy treatment planning data available
- Corresponding healthcare data available to infer toxicity events (ref previous work by Lemanska et al)
Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Edinburgh Coordinator of this site? Confirm its status | Edinburgh | United Kingdom | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.